DanCann Pharma A/S targeting annual revenue of approx. DKK 60-100 million – and with several new partner agreements in the pipeline
COPENHAGEN, Denmark, November 1, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Company is in talk and negotiations with a number of new international partners as a further addition to the WEECO Pharma GmbH (“WEECO Pharma”) agreement, which DanCann Pharma signed in August.DanCann Pharma expects to hit its commercial breakthrough with increased sales activities following the expected approval of the production facilities in Q4 2022, breakeven during 2024 and an expected revenue in 2025–2027 of